CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown on IO-BCG Combinations
CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown on IO-BCG Combinations

Gordon Brown, DO, Summit Health, breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG and the potential for a paradigm shift in treatment.

He also previews upcoming trials like POTOMAC and KEYNOTE-676 that could further reshape the standard of care.

Advertisement

Latest News

Clonal Mutations More Common After 177Lu-PSMA-617 Than Cabazitaxel
Clonal Mutations More Common After 177Lu-PSMA-617 Than Cabazitaxel
Lauren Dembeck, PhDCRPC | May 29, 2025
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Enzalutamide Plus ADT Maintains Long-Term OS Benefit in Patients With mHSPC
Enzalutamide Plus ADT Maintains Long-Term OS Benefit in Patients With mHSPC
Lauren Dembeck, PhDmHSPC | May 29, 2025
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Darolutamide Preserves Patient-Relevant HRQoL in Men With mHSPC
Darolutamide Preserves Patient-Relevant HRQoL in Men With mHSPC
Lauren Dembeck, PhDmHSPC | May 29, 2025
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Long-Term Data Confirms Survival Benefit of Adjuvant Pembrolizumab in Patients With ccRCC
Long-Term Data Confirms Survival Benefit of Adjuvant Pembrolizumab in Patients With ccRCC
Lauren Dembeck, PhDRenal Cell Carcinoma | May 29, 2025
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Tumor Environment and Circulating Factors Affect Response in aRCC
Tumor Environment and Circulating Factors Affect Response in aRCC
Lauren Dembeck, PhDAdvanced Renal Cell Carcinoma | May 29, 2025
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Show Promise in MIBC
Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Show Promise in MIBC
Lauren Dembeck, PhDMuscle Invasive Urothelial Carcinoma | May 29, 2025
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
Sasanlimab in Combination With BCG Improves EFS Over BCG Alone in BCG-naive, high-risk NMIBC With CIS or T1 Tumors
Sasanlimab in Combination With BCG Improves EFS Over BCG Alone in BCG-naive, high-risk NMIBC With CIS or T1 Tumors
Lauren Dembeck, PhDUrothelial Carcinoma | May 29, 2025
Updated CREST trial explores sasanlimab plus BCG in BCG-naive, high-risk NMIBC, with new insights by disease stage and tumor.
Circulating Tumor DNA Outcomes in Patients With MIBC on Perioperative Durvalumab
Circulating Tumor DNA Outcomes in Patients With MIBC on Perioperative Durvalumab
Lauren Dembeck, PhDMuscle Invasive Urothelial Carcinoma | May 29, 2025
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Enfortumab + Pembro Boosts PFS Versus Chemo in Untreated LA/mUC
Enfortumab + Pembro Boosts PFS Versus Chemo in Untreated LA/mUC
Lauren Dembeck, PhDAdvanced Urothelial Carcinoma | May 29, 2025
Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
HRR Mutations and mCRPC: When and How to Integrate PARP Inhibitors
HRR Mutations and mCRPC: When and How to Integrate PARP Inhibitors
L. Crain Garrot, MDProstate Cancer | May 29, 2025
The panel concludes with a discussion on the early use of PARP inhibitors in patients with DNA repair mutations like BRCA1/2.
Darolutamide, ARANOTE, and Navigating Payment
Darolutamide, ARANOTE, and Navigating Payment
L. Crain Garrot, MDProstate Cancer | May 29, 2025
The panel delves into how de novo metastases signal more aggressive prostate cancer biology.
From SPOP to TP53: How Molecular Markers Shape Treatment Pathways
From SPOP to TP53: How Molecular Markers Shape Treatment Pathways
L. Crain Garrot, MDProstate Cancer | May 29, 2025
The panel weighs the role of next-generation sequencing and emphasizes how SPOP, TP53, and RB1 guide treatment decisions.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Evan Kovac, MDProstate Cancer | May 19, 2025
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mHSPC/mCSPC
mHSPC/mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 416: ASCO 2025 Preview
Episode 416: ASCO 2025 Preview
Returning guest Silke Gillessen joins the show to chat with Tom and Brian on what they are looking forward to at ASCO 2025.
# Posted on May 20, 2025
Episode 413: The Uromigos Score for Advanced Prostate Cancer
Episode 413: The Uromigos Score for Advanced Prostate Cancer
Returning guests Drs. Gillessen and Sweeney discuss the value of treatments for advanced prostate cancer.
# Posted on May 13, 2025
# Uromigos-Prostate Cancer
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMIBC From SunRISe-1n
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMIBC From SunRISe-1n
Dr. Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1.
# Posted on May 6, 2025
# Uromigos-Bladder Cancer

Conference Coverage

Live meeting highlights

Clonal Mutations More Common After 177Lu-PSMA-617 Than Cabazitaxel
Lauren Dembeck, PhDCRPC | May 29, 2025
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Read More
Enzalutamide Plus ADT Maintains Long-Term OS Benefit in Patients With mHSPC
Lauren Dembeck, PhDmHSPC | May 29, 2025
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Read More
Darolutamide Preserves Patient-Relevant HRQoL in Men With mHSPC
Lauren Dembeck, PhDmHSPC | May 29, 2025
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Read More
Long-Term Data Confirms Survival Benefit of Adjuvant Pembrolizumab in Patients With ccRCC
Lauren Dembeck, PhDRenal Cell Carcinoma | May 29, 2025
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Read More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |